Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wierzbicki, A. S
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The role of dyslipidaemia in coronary heart disease

Anthony S Wierzbicki

Consultant Chemical Pathologist, St Thoma's Hospital, Lambeth Palace Road, London, SE1 7EH, UK, Anthony.Wierzbicki{at}kcl.ac.uk

The role of cholesterol in cardiovascular disease (CVD) and especially coronary heart disease (CHD) is well established. Epidemiological studies show consistent relationships between total cholesterol, low-density lipoprotein cholesterol (LDL-C) and CHD risk. These same studies show a strong inverse relationship for levels of high-density lipoprotein cholesterol (HDL-C) and CHD risk and a possible relationship for triglycerides.

The metabolic syndrome is a common syndrome affecting 20—25% of the population whose features include abdominal obesity, low-HDL-C, elevated triglycerides, hypertension, hyperglycaemia, hyperinsulinaemia, elevated inflammatory markers, renal dysfunction and microalbuminuria. In the UKPDS study in type 2 diabetes that compared the effects of improved glycaemic and blood pressure control, though some benefit was seen on cardiovascular end points with tighter control, the critical factors predisposing to later macrovascular disease were LDL-C and HDL-C.

There is extensive trial evidence for the benefits of statins in secondary and primary prevention. All guidelines state these are first-line agents for the treatment of cardiovascular risk. Statins have undoubted benefits in the treatment of patients with type 2 diabetes. Statins are also effective in reducing CVD in patients with metabolic syndrome. However, the focus on the benefits of statin therapy has limited discussion of their limitations. In all statin trials to date they reduce CVD events by 25—30% with the largest reduction in the GREACE study being 50%. Only high-dose statin therapy prevents progression of atherosclerosis. Thus, a single minded concentration on LDL-C may underestimate the benefits of a more integrated approach to the management of hyperlipidaemia.

Key Words: coronary heart disease • cholesterol • HDL-cholesterol • diabetes • risk.

References

  • Keys A., Menotti A., Aravanis C. et al. The seven countries study: 2,289 deaths in 15 years. Prev Med 1984;13:141-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Menotti A., Keys A., Aravanis C. et al. Seven Countries Study. First 20-year mortality data in 12 cohorts of six countries. Ann Med 1989;21: 175-9.[Web of Science][Medline] [Order article via Infotrieve]
  • The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA 1976;235:825-7.[Abstract/Free Full Text]
  • Bucher HC, Griffith LE, Guyatt GH Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999;19:187-95.[Abstract/Free Full Text]
  • Wierzbicki AS, Poston R., Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003;99:95-112.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
  • Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart 1998;80(suppl 2):S1-S29.[Free Full Text]
  • Pyorala K., Wood D. Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced. Eur Heart J 1998;19:1413-15.[Free Full Text]
  • Athyros VG, Mikhailidis DP, Papageorgiou AA et al. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004;20:1691-701.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • James PT, Rigby N., Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004: 11:3-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ginsberg HN, Stalenhoef AF The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J Cardiovasc Risk 2003;10:121-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stallones RA The rise and fall of ischemic heart disease. Sci Am 1980;243:53-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Sijbrands EJ, Westendorp RG, Defesche JC et al. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 2001;322:1019-23.[Abstract/Free Full Text]
  • Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Downs JR, Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.[Abstract/Free Full Text]
  • Sacks FM, Tonkin AM, Craven T. et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002;105:1424-8.[Abstract/Free Full Text]
  • Sattar N., Gaw A., Scherbakova O. et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-19.[Abstract/Free Full Text]
  • Haffner SM, Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339: 229-34.[Abstract/Free Full Text]
  • Nishtar S., Wierzbicki AS, Lumb PJ et al. Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. Curr Med Res Opin 2004;20:55-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wierzbicki AS, Nishtar S., Lumb PJ et al. Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. Heart 2005;91:1003-07.[Abstract/Free Full Text]
  • Jaber LA, Brown MB, Hammad A. et al. The prevalence of the metabolic syndrome among arab Americans. Diabetes Care 2004;27:234-8.[Abstract/Free Full Text]
  • Abdul-Ghani MA, Sabbah M., Muati B. et al. High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. Isr Med Assoc J 2005;7:143-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Onat A., Ceyhan K., Basar O. et al. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels -a prospective and cross-sectional evaluation. Atherosclerosis 2002;165: 285-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Castelli WP, Garrison RJ, Wilson PW et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. Framingham study. JAMA 1986;256:2835-8.[Abstract/Free Full Text]
  • Abbott RD, Wilson PW, Kannel WB et al. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arterioclerosis 1988;8:207-11.
  • Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70:733-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Goldbourt U., Yaari S., Medalie JH Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13.[Abstract/Free Full Text]
  • Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.[Abstract/Free Full Text]
  • Sacks FM The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Austin MA, Hokanson JE, Edwards KL Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hokanson JE, Austin MA Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-19.[Medline] [Order article via Infotrieve]
  • Assmann G., Schulte H., Funke H. et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19 (suppl M):M8-M14.[Medline] [Order article via Infotrieve]
  • Austin MA Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000;2:200-07.[Medline] [Order article via Infotrieve]
  • Haim M., Benderly M., Brunner D. et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 1999; 100:475-82.[Abstract/Free Full Text]
  • Turner RC, Millns H., Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.[Abstract/Free Full Text]
  • Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Caro J., Klittich W., McGuire A. et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997;315:1577-82.[Abstract/Free Full Text]
  • Robins SJ, Collins D., Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91.[Abstract/Free Full Text]
  • Canner PL, Furberg CD, Terrin ML et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. Cardiovasc Diabetol 2004;
  • Laing SP, Swerdlow AJ, Slater SD et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003;46:760-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group. Diabetes Care 1992;15:886-94.[Abstract]
  • Nathan DM, Lachin J., Cleary P. et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294-303.[Abstract/Free Full Text]
  • Collins R., Armitage J., Parish S. et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Walldius G., Jungner I., Holme I. et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cromwell WC, Otvos JD Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004;6:381-7.[Medline] [Order article via Infotrieve]
  • Sacks FM, Alaupovic P., Moye LA et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000;102:1886-92.[Abstract/Free Full Text]
  • Onat A., Hergenc G., Sansoy V. et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003;168:81-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Olsson AG, Holmquist L., Walldius G. et al. Serum apolipoproteins, lipoproteins and fatty acids in relation to ischaemic heart disease in northern and southern European males. Acta Med Scand 1988;223:3-13.[Web of Science][Medline] [Order article via Infotrieve]
  • Bjorkegren J., Boquist S., Samnegard A. et al. Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease. Circulation 2000;101:227-30.[Abstract/Free Full Text]
  • Wierzbicki AS Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Curr Med Res Opin 2005;21:299-306.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 1 suppl, S2-S6 (2005)
DOI: 10.1177/14746514050050010201
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wierzbicki, A. S
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?